🔴 BreakingDrug approvalOPENFDAApr 4
The FDA has approved a new drug called FOUNDAYO (orforglipron), made by Eli Lilly. This approval means the medication is now available for patients to use. The drug was officially approved on April 1, 2026.
WHY IT MATTERSWithout information about which rare disease FOUNDAYO treats, we cannot specify the patient impact — the article lacks details about the condition it addresses or which patients are eligible.
🔴 BreakingDrug approvalRSSApr 3
The FDA has approved a new drug called Avlayah to treat Hunter syndrome, a rare genetic disease that affects the brain and nervous system. Hunter syndrome happens when the body can't break down certain substances properly, causing serious health problems over time. This approval means patients with Hunter syndrome now have a new treatment option available to help manage the neurologic symptoms of their condition.
WHY IT MATTERSThis is the first FDA approval of Avlayah specifically for the neurologic manifestations of Hunter syndrome, offering patients a new therapeutic option for managing brain and nervous system symptoms that were previously difficult to treat.
🔴 BreakingDrug approvalRSSApr 3
The FDA approved a new drug called Foundayo (orforglipron) on a special fast-track program called the National Priority Voucher program. This is the fifth drug approved through this program, which helps speed up approval for medicines that address important health needs. The program is designed to get helpful new treatments to patients faster.
WHY IT MATTERSThis approval demonstrates the National Priority Voucher program is working to bring new treatment options to patients with rare diseases more quickly than the standard FDA review process.
🔴 BreakingDrug approvalOPENFDAApr 3
The FDA has approved a new drug called FLAVALTA, which contains lidocaine and epinephrine. Lidocaine is a numbing medication, and epinephrine helps control bleeding. This approval means the drug is now available for patients to use, though the specific medical condition it treats is not detailed in this announcement.
WHY IT MATTERSThis approval makes a new numbing and bleeding-control medication available to patients who need it, though the specific rare disease indication requires clarification from your doctor or the full prescribing information.